{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:38:19Z","timestamp":1794965899265,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck & Co."},{"name":"Inc."}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1093\/annonc\/mdz135","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T07:14:58Z","timestamp":1555571698000},"page":"1080-1087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":783,"title":["Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study"],"prefix":"10.1016","volume":"30","author":[{"given":"U.A.","family":"Matulonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Shapira-Frommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Lisyanskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8981","authenticated-orcid":false,"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.B.","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Rudaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Katchar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ruman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1093\/annonc\/mdz135_bb0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"9951","key":"10.1093\/annonc\/mdz135_bb0015","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdz135_bb0020","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1093\/annonc\/mdz135_bb0025","series-title":"Ovarian Cancers: Evolving Paradigms in Research and Care","article-title":"National Academies of Sciences, Engineering, and Medicine","year":"2016"},{"issue":"3","key":"10.1093\/annonc\/mdz135_bb0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2016.03.005","article-title":"Moving beyond the platinum sensitive\/resistant paradigm for patients with recurrent ovarian cancer","volume":"141","author":"Alvarez","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdz135_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol Oncol Res Pract"},{"issue":"9","key":"10.1093\/annonc\/mdz135_bb0040","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1093\/annonc\/mdz135_bb0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdz135_bb0050","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2016.34.15_suppl.5533","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity","volume":"34","author":"Disis","year":"2016","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1093\/annonc\/mdz135_bb0055","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz135_bb0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): a phase 1\/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz135_bb0065","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz135_bb0070","article-title":"A phase I\/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891)","volume":"35","author":"Odunsi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"436","key":"10.1093\/annonc\/mdz135_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci Transl Med"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz135_bb0080","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2017.35.15_suppl.5513","article-title":"Pembrolizumab in patients (pts) with PD-L1-positive (PD-L1(+)) advanced ovarian cancer: updated analysis of KEYNOTE-028","volume":"35","author":"Varga","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz135_bb0085","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1093\/annonc\/mdz135_bb0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz135_bb0095","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1093\/annonc\/mdz135_bb0100","doi-asserted-by":"crossref","first-page":"e1277308","DOI":"10.1080\/2162402X.2016.1277308","article-title":"Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PD-L1 expression","volume":"6","author":"Howitt","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1093\/annonc\/mdz135_bb0105","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"issue":"25","key":"10.1093\/annonc\/mdz135_bb0110","doi-asserted-by":"crossref","first-page":"17501","DOI":"10.18632\/oncotarget.24770","article-title":"BRCA1\/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer","volume":"9","author":"Wieser","year":"2018","journal-title":"Oncotarget"},{"issue":"14","key":"10.1093\/annonc\/mdz135_bb0115","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1158\/1078-0432.CCR-17-1805","article-title":"Exceptional response to pembrolizumab in a metastatic, chemotherapy\/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement","volume":"24","author":"Bellone","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdz135_bb0120","unstructured":"Merck KGaA and Pfizer. Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant\/Refractory Ovarian Cancer. Press release. Published 19 November 2018. www.emdgroup.com\/en\/news\/avelumab-1x-11-2018.html (25 January 2019, date last accessed)."},{"key":"10.1093\/annonc\/mdz135_bb0125","unstructured":"Merck KGaA and Pfizer. Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer. Press release. Published 21 December 2018. www.emdgroup.com\/en\/news\/javelin-ovarian-100-21-12-2018.html (25 January 2019, date last accessed)."},{"key":"10.1093\/annonc\/mdz135_bb0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.molimm.2017.04.012","article-title":"Epigenetics and immunotherapy: the current state of play","volume":"87","author":"Dunn","year":"2017","journal-title":"Mol Immunol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdz135_bb0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2018.04.085","article-title":"Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients","volume":"149","author":"Matulonis","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdz135_bb0140","doi-asserted-by":"crossref","first-page":"315ra188","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"Muller","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419312414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419312414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz135\/28756641\/mdz135.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/7\/1080\/28951674\/mdz135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:06:41Z","timestamp":1668694001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419312414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0923753419312414"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz135","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/annonc\/mdz135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 THE AUTHORS. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}